Pharmacie française en ligne: Acheter des antibiotiques sans ordonnance en ligne prix bas et Livraison rapide.

December 17, 2008

December 17, 2008
Harold F. Farber, M.D.
Home Address:
190 Presidential Blvd.
Unit 615
Bala Cynwyd, PA 19004
Office Addresses:
822 Montgomery Avenue

Education:
1975-79BA Penn State University
1979-83 MD Albany Medical College
Postgraduate Training and Fellowship Appointments:
1983-84 – Intern in Medicine, Albany Medical Center
1984-87 – Resident in Dermatology, Thomas Jefferson University Hospital
Faculty Appointments:
1994 – Present – Attending Physician, Hahnemann University Hospital
1995 – Present – Attending Physician, Lankenau Hospital
Specialty Certification:
1987 American Board of Dermatology
Licensure:
Pennsylvania
Awards, Honors & Membership in Honorary Society
1977 Phi Beta Kappa
2001 Main Line Top Doctors
2007 & 2008 To American’s Top Physicians Award
2008 Main Line Top Doctors
Membership in Professional and Scientific Societies:
American Medical Association
Pennsylvania Medical Society
American Society for Dermatologic Surgery
Philadelphia County Medical Society
American Academy of Dermatology
Pennsylvania Academy of Dermatology
Philadelphia Society of Facial Plastic Surgeons
Dermatology Foundation
American Academy of Cosmetic Surgery
Thomas Jefferson University – Volunteer Faculty Member
Council for Nail Disorders
Medical Mycological Society of Americas
Photomedicine Society
Golden Slipper Club and Charities
Albany Medical College Mentor Program for Students on Career Related Issues
American Society of Dermatologic Surgeons
Independence Blue Cross Medical Policy Consultant
Teaching
In Office Lankenau Residents
Arcadia University Physician Assistant Program
Mentoring of College Alma Mater (Penn State University – pre medical students)
Lectures:
Guest Lecturer Wills Eye Institute Continuing Medical Education. Eyelid and Facial Rejuvenation; A
Multidisciplanary Approach 04/08
Guest Lecturer at a Patient Education Seminar in the Use of New Therapeutic Treatments for Psoriasis at
Huntingdon Valley, PA
Participant in a Raptiva Speaker Training Seminar
Norvartis Pharmaceuticals Presentation to Family Practitioners: Usage of Topical Immunomodulators in
Dermatology
Participant: Novartis consultant Network Regional Advisory Committee
Participant: Genetech Regional Advisory Board Meeting: “Usage of Biologics in Psoriasis”
Warner-Chilcott Pharmaceuticals Lecturer to Dermatology Physicians and Physician Assistants. “Acne
Case Studies in Dermatology”
Speaker for Novartis in “Advances in the Treatment of Atopic Dermatitis” (06/04)
Guide to America’s Top Physicians” Consumers Research Council of America Recipient Award
Main Line Today “Top Docs” Choice Award
Warner Chilcott Speakers Bureau/Guest Lecturer – Doxycycline antibiotics in the Treatment of Acne
Seminars in Psoriasis Speakers Participant Faculty Member International CME Lecture Series
Aventis Pharmaceuticals Inc. Speaker Participant – Antihistamine Usage in Dermatology
Novartis Consultant Network Participant and Guest Lecturer on Topical Immunomodulator usage in
Eczema to Family Practitioners and Dermatologists
Amgen Regional Speakers Training Participant
Connections Magazine Dermatologic Consultant
Pennsylvania Osteopathic Family Physicians Society Invited Guest Lecturer on Therapeutic Advances in
the Treatment of Eczema 9/02
Covance Health Economics and Outcomes Services Inc. – Consultant Participant
Physician Satisfaction and Payor coverage and Reimbursement for treatments using the Levulan Kerastick
Fujisawa Dermatology Speakers Update Meeting Participant and Lecturer 6/02
Galderma Laboratories Speakers Program Participant/Speaker forum 6/02
Connetics Consultant Dermatology Advisory Meeting Connetics, OLUX Investigator Meeting Participant
Connetics Speakers Training Meeting Participant
Novartis Advisory Board Speaker – Understanding the Changing Landscape of Eczema
Treatment for Family Practitioners/Internal Medicine 5/02
Novartis Pharmaceutical Famvir Speaker Training Meeting Particpant – AZ 2/02
Novartis Advisory Board Speaker
Topical Immunomodulator usage in Eczema. 2. Antiviral therapy for Herpetic Infections. 3. Onychomycosis: Treating and Managing Your Diabetes and other High Risk Patients, Family Practitioners Audience 2/02. Elidel Speakers Training Meeting Participant Cutivate Speakers Training Meeting Participant Fujisawa Dermatology Visiting Faculty Program Lecturer, Multiple presentations Including: Pennsylvania, California, Utah, North Carolina, Maine, and Illinois lectures Purdue Pharmaceutical L.P. Speakers Bureau Member Novartis Pharmaceuticals Corporation Preceptor Guest Lecturer: Protopic: Safety, Efficacy, and Realistic Expectations. San Diego Dermatology Meeting (10/01) Guest Lecturer: Differential Diagnosis and Management Issues Regarding Atopic Dermatitis. Philadelphia Family Physicians Dinner Meeting (09/01) Guest Lecturer: Diagnostic and Therapeutic Options in the Treatment of Onychomycosis Philadelphia Family Physicians Dinner Meeting (09/01) Guest Lecturer: Therapeutic Advancement in the Treatment of Eczema. Fujisawa Corporation New Jersey (08/01) Guest Lecturer: Safety, Efficacy, Study Design and Clinical Usage of Tecrolimus in the Treatment of Atopic Dermatitis. Fujisawa Corporation. Philadelphia (07/01) Guest Lecturer: Onychomycosis – Therapeutic Options. Novartis Pharmaceuticals. Phildelphia (04/01) Guest Lecturer: Clinical Experience using Current Antiviral Therapy. Novartis Pharmaceuticals. Philadelphia (2/01) Consultant Preceptor Bristol-Meyers Squibb Company for Sales Representative Training (04/01) Guest Lecturer: Clinical Experience, Efficacy and Alternatives to Lamisil and Famvir usage in an active Clinical Dermatology Practice. Philadelphia (06/01) Participated in Advisory Board Meeting for Managed Care evaluation of Fujisawa’s new product for Atopic Dermatitis (01/01) Philadelphia Dermatology Society invited guest lecturer monthly meeting. A noval treatment for pre cancerous Keratosis-Phase III Clinical Trial Results (01/01) Guest Lecturer on Photodynamic Treatment of Actinic Keratosis at Palm Beach Dermatology Society (12/00) Guest Lecturer in Boston for “Review & Results” of Phase III Clinical Trial in Photodynamic Treatment of Actinic Keratosis Guest Lecturer on Photodynamic Treatment of Actinic Keratosis at Broward County Dermatology Society (12/00) Connetics Corportion National Speakers’ Bureau – Lecture on Safe and Effective Usage of Topical Steroids (10/00) Novartis Pharmaceuticals Lecture on Current Treatment of Onychomycosis (08/00) SmithKline Beecham Lecture on Famvir and Common Skin Dermatoses (06/00) BioGlan Pharma Drug Representative Training Program Lecturer (1/00) BioGlan Pharma Physician Advisory Board Participant WPEN Radio “Ask the Doctor” Medical Guest on Dermatology Procedures AIDS Fund Medical Expert Participant for Tretment of Alopecia (ll/99) SmithKline Drug Representative Training Program Lecturer on Famcyclovir Schering Local Clinical Lecture Series to Pharmacists,; Exposure to Dermatology Schering Local Clinical Lecture Series to Medical Residents; Common Skin Dermatoses Schering Local Clinical Lecture Series to Family Practitioners; Dermatoses in General Practice American Society of Laser Medicine and Surgery, Guest Speaker on 810 nm Diode Laser Theory, Procedure, Results Guest Lecturer at Pennsylvania Academy of Dermatology (9/86) Cover Article – Philly Health and Fitness Magazine, “Philly’s Fittest Physicians” National Disease and Therapeutic Index Physician Panel Profile Participant National Ambulatory Medical Care Survey Participant Fujisawa Guest Lecturer on Eczema Central Valley Dermatology Society, “Clinical Safety and Effect of Protopic Use in Eczema from Multiple Clinical Trials” IMS Health Pharmaceutical Promotion Survey Participant Cynosure Guest Lecturer on A Dermatological Conversation on Fractional Resurfacing Technology. The Pyramid Club, Philadelphia, PA (06/20/07) Guest Lecturer on Steroid Responsive Dermatoses. Hahnemann University Hospital Residents. Tequila Restaurant, Philadelphia, PA (11/07/07) Volunteer – Olay Skin Cancer Public Screening Participant (2007) Guest Lecturer on Current Issues in Dermatology. Thomas Jefferson University Hospital Residents. Susanna Foo Restaurant, Philadelphia, PA (01/23/08) Warner Chilcott Guest Lecturer on Acne Therapeutics. Borgata Hotel, Atlantic City, NJ (07/18/08) Warner Chilcott Guest Lecturer on Psoriasis Therapeutics (08/01/08)
Bibliography:
Publications, Peer reviewed:
Treatment of chronic plaque psoriasis by
selective targeting of memory effector T lymphocytes. 345(4):248-55, 2001 Jul 26.
Etanercept as monotherapy in patients with psoriasis.349(21):2014-22, 2003 Nov 20.
Daniel J. Piacquadio; Diana M. Chen; Harold F. Farber; Joseph F. Fowler, Jr; Scott D. Glazer; J. John
Goodman; Luciann L. Hruza; Edward W. B. Jeffes; Mark R. Ling; Tania J. Phillips; Tena M. Rallis;
Richard K. Scher; Charles R. Taylor; Gerald David Weinstein Photodynamic Therapy With
Aminolevulinic Acid Topical Solution and Visible Blue Light in the Treatment of Multiple Actinic
Keratoses of the Face and Scalp: Investigator-Blinded, Phase 3, Multicenter Trials

Arch Dermatol. 140(1):41-46, 2004.
Farber, Harold F. Removal of a Spider angioma with Diode Laser Photoderm: Clinical Study and
Photography Techniques for Dermatologist . Vol 2, No 2, 7-9, 2000.
Massive lipoma of the palm. 11(5):431-3. 1983 Nov.

Publications, Non-Peer reviewed:

Norton,L and Farber,H. Point-Counterpoint: Should Dermatologists Dispense Cosmetics - Skin and
Aging Journal of Geriatric Dermatology, Vol 6, Number 1, 74-77, 1998

Clinical Research:

Principal Investigator: Open-Label, Multi-Center Study to Evaluate the Transition from XXXXXX
Therapy to Approved Systemic and/or Phototherapy Psoriasis Treatments in Adults with Moderate to
Severe Plaque Psoriasis.
Principal Investigator: A Multicenter, Double-Blind, Randomized, Vehicle Controlled, Parallel-Group
Study to Determine the Therapeutic Equivalence of Two XXXXXX 0.75% Gel Formulations in Subjects
with Rosacea.
Principal Investigator: A Multicenter, Randomized, Placebo-Controlled Phase 2 Study Evaluating the
Effect of 2 mg, 15mg or 50 mg XXXXXX Treatment Compared to Placebo in Patients with Psoriasis.
Principal Investigator: A Phase IIIb, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled,
Multicenter Study to Evaluate the Safety of l.0 mg/kg Subcutaneously Administered XXXXXX in Adults
with Moderate to Severe Plaque Psoriasis who are candidate for Systemic Therapy.
Principal Investigator: An Open-label, Multicenter Study to Evaluate the Safety of 1.0 mg/kg
Subcutaneously Administered XXXXXX in Adults with Plaque Psoriasis Previously Enrolled in Study
XXXXXXX
Principal Investigator: A Multi-Center, Community-Based Trial to Assess the Efficacy and Safety of
XXXXXXX Cream in the Treatment of Facial Melasma
Principal Investigator: A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety
and Efficacy of XXXXX 0.12% in the Treatment of Moderate to Severe Atopic Dermatitis
Principal Investigator: Multicenter Dosing Ranging Study of the Safety and Efficacy of XXXXX in
Psoriasis
Principal Investigator: A Randomized, Double-Blind, Placebo-Controlled, Exploratory Pharmacogenomic
Study of Recombinant Human Interleukin Eleven (rhIL-11) in Patients with Active Psoriasis
Principal Investigator: A Phase II Multicenter, Randomized, Investigator-Blinded Study to Evaluate the
Safety and Efficacy of XXXXX, 1%, versus Vehicle Foam and XXXXX Topical Gel, 1%, in Subjects with
Acne Vulgaris
Principal Investigator: A Phase IIIb, Randomized, Double Blind, Parallel Group, Placebo-Controlled,
Multicenter Study to Evaluate the Safety of 1.0 mg/kg Subcutaneously Administered XXXXX in Adults
with Moderate to Severe Plaque Psoriasis
Principal Investigator: Phase I Multiple-Dose, Dose-Escalation Study to Evaluate the
Safety of XXXXX Administered by Subcutaneous Injection to Patients with Plaque Psoriasis
Principal Investigator: Phase I-II Open-Label, Multiple Dose, Pharmacokinetic,
Pharmacodynamic, and Safety Study of XXXXX in Patients with Psoriasis
Principal Investigator: A Phase III, Randomized, Double Blind, Parallel-Group, Placebo-
Controlled, Multicenter, Multidose Study to Evaluate the Efficacy and Safety of
Subcutaneously Administered XXXXX in Adults with Moderate to Severe Plaque Psoriasis who are
candidates for Systemic Therapy
Principal Investigator: Efficacy and Safety Comparison of XXXXX Cream vs Two
Trials of Filters (XXXXX) in Patients with Polymorphous Light Eruption in
Outdoor Conditions
Principal Investigator: A Comparative Study of Inter-rater and Intra-rater Variability of
Psoriasis Area and Severity Index (PASI), Psoriasis Global Assessment (PGA),
and Lattice System Global Psoriasis Score (LSGPS) in Subjects with Active
Psoriasis
Principal Investigator: An Open-Label Study to Detertmine the Tolerability and Efficacy
of Repeat Courses of XXXXX in Subjects with Chronic Plaque Psoriasis
Principal Investigator: A Randomized, Double-Blind Comparison of Intravenous
XXXXX vs Placebo in Subjects with Chronic Plaque Psoriasis
Principal Investigator: A Blinded, Multiple-Dose Study to Determine the Tolerability of
Repeated Courses of XXXXX in Subjects with Moderate, Moderate to Severe, and Severe Plaque Psoriasis
Principal Investigator: A Phase II/III Multi-Center, Double-Blind, Parallel-Group,
Efficacy and Safety Study of Once-A-Day Topical Administration of Three
Concentrations of XXXX Compared to XXXXX in Subjects with Plaque Psoriasis
Principal Investigator: An Open-Label, Long Term Study of the Safety and Tolerability
of Oral XXXXX in Patients with Plaque Psoriasis
Principal Investigator: A Double-Blind, Randomized, Parallel, Placebo-Controlled,
Multi-Center Study to Evaluate the Safety and Clinical Equivalence of XXXXX
in Patients with Moderate to Severe Ichthyosis Vulgaris
Principal Investigator: An Open-Label Study to Evaluate the Safety of Topically Applied XXXXX Ointment for Treatment to Atopic Dermatitis Consultant Diomed Labs: Development and Application with Specific Criteria and Usage of Diode Laser in a Clinical Setting Principal Investigator: A Phase III Study of Photodynamic Therapy with XXXXX Topical Solution and Visible Blue Light in the Treatment of Multiple Actinic Keratoses Principal Investigator: A Phase III, Randomized, Double-Blind Study Comparison of Topically Applied XXXXX Ointment vs Vehicle Ointment in Adult Patients with Atopic Dermatitis Principal Investigator: A Parallel-Arm, Double Blind, Placebo-Controlled, Efficacy Study of XXXXX Lotion (12%) and Lac-Hydrin in Patients with Moderate or Greater Ichthyosis Vulgaris Principal Investigator: Open-Label, Long Term, Follow-Up Study to Evaluate the Safety of Topically Applied XXXXX Ointment for the Treatment of Atopic Dermatitis Principal Investigator: Double-Blind, Randomized, Parallel, Placebo-Controlled, Multi- Center Study to Evaluate the Safety and Clinical Equivalence of a Generic XXXXX vs XXXXX in Patients with Moderate to Severe Ichthyosis Vulgaris Principal Investigator: A Blinded, Multiple-Dose Study to Determine the Tolerability of Repeated Courses of XXXXX in Subjects with Moderate, Moderate to Severe, and Severe Plaque Psoriasis Principal Investigator: An Open-Label Study to Determine the Safety and Efficacy of Repeated Courses of XXXXX in Subjects with Chronic Plaque Psoriasis Investigator: A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Multicenter Study Assessing the Effects of XXXXX and XXXXX in the Improvement of Moderate to Severe Age-Related Skin Changes in Post-menopausal Women Principal Investigator: A 6-month Open-Label, Multi-National Effectiveness, and Safety Study of XXXXX cream 1% in Subjects with Atopic Dermatitis Principal Investigator: A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of XXXXX Foam, 0.05% in the treatment of Mild to Moderate Plaque-type Psoriasis of Non-Scalp Regions Principal Investigator: Vehicle-Controlled, Double-Blind Study to Assess the Safety and Efficacy of XXXXX 5% Cream Applied Once Daily 2 Days per Week for the Treatment of Actinic Keratoses on the Head Principal Investigator: A Phase I-II, Open Label, Multiple-Dose Pharmacokinetic, Pharmacodynamic, and Safety Study of Humanized XXXXX Antibody in Patients with Psoriasis Principal Investigator: A Phase I Multi Dose, Dose-Escalation Study to Evaluate the Safety of XXXXX, a Humanized Monoclonal Antibody That Binds to CD2 Receptor, Administered by Subcutaneous Injection to Patients with Plaque Psoriasis Principal Investigator: A Phase II Randomized, Placebo-Controlled, Double-Blind Study of XXXXX, A Humanized Monoclonal Antibody That Binds to CD2 Receptor, Administered by Subcutaneous Injection to Patients with Plaque Psoriasis Principal Investigator: A Randomized, Double-Blind, Placebo-Controlled Study of XXXXX 0.03% vs. Vehicle Ointment in Pediatric Patients with Mild to Moderate Atopic Dermatitis Principal Investigator: A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of a XXXXX Topical Patch in the Treatment of Distal and Subungual Onychomycosis of the Great Toenail Principal Investigator: A Multi-Center, Double-Blind, Placebo Controlled, Parallel Group Study Comparing the Bioequivalence of XXXXX 0.75% and XXXXX 0.75% in the Treatment of Inflammatory Papules and Pustules of Rosacea Principal Investigator: An Open-Label, Multi-Center, Phase IV Study of XXXXX for the treatment of Mild and Moderate Acne Vulgaris. Principal Investigator: A Randomized, Double-Blind, Double-Dummy, Placebo- Controlled Study of the Safety and Efficacy of XXXXX, 2% versus XXXXX 2% Cream in the Treatment of Seborrheic Dermatitis Principal Investigator: A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Trial to Assess the Safety and Efficacy of 0.1% XXXXX in the Treatment of Psoriasis on the Face or Intertriginous (Inverse) Areas Principal Investigator: The Safety and Efficacy of XXXXX Gel, 0.3% as Compared to XXXXX Gel, 0.1% and XXXXX Gel, Vehicle in the Treatment of Acne Vulgaris Principal Investigator: A 12-month, Multicenter, Open-Label, Non-Comparative Design Study of 5% XXXXX Gel in Patients with Acne Vulgaris Principal Investigator: A Randomized, Double-Blind, Placebo-Controlled, Exploratory Pharmacogenomic Study of Recombinant Human Interleukin XXXXX in Patients with Active Psoriasis Principal Investigator: Phase II//III Multicenter Study of the Safety and Efficacy of XXXXX in Psoriasis Principal Investigator: The XXXXX Cream B.E.S.T. in Acne Trial Principal Investigator: A Phase III Evaluator-Blind, Randomized, Parallel-Group Study to Determine the Effect of the XXXXX Patch, XXXXX 2 mg., on the Healing of Recurrent Minor Aphthous Ulcers as Compared with XXXXX or No Treatment Principal Investigator: A Multi-Center, Double-Barrier, Vehicle-Controlled Study of the Efficacy and Safety of XXXXX Shampoo and XXXXX Shampoo in the Three Times Weeky Treatment of Seborrheic Dermatitis of the Scalp for 4 weeks Principal Investigator: A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Three Dose Levels of XXXXX in the Treatment of Chronic Plaque Psoriasis Principal Investigator: A Phase III, Randomized, Double-Blind, Parallel Group, Multicenter, Efficacy and Safety Study of XXXXX Versus XXXXX for the Treatment of Onychomycosis Principal Investigator: A Multi-Center, Double-Blind, Placebo Controlled, Dose-Escalation Study of the Efficacy and Safety of 3 Doses of XXXXX Capsules (XXmg) in the Treatment of Plaque Psoriasis for 8 weeks Principal Investigator: A Multicenter, Open Label Study to Observe the Effect of XXXXX on Joint and Skin Disease in Subjects with Psoriatic Arthritis Principal Investigator: A 12 Week, Multicenter, Double-Blind, Randomized, Parallel Design Study of XX% XXXXX Topical Gel and Vehicle Control in Patients with Acne Vulgaris Principal Investigator: A Randomized, Double-Blind, Vehicle Controlled, Parallel-Group, Multicenter Study to Demonstrate the Safety and Clinical Equivalence of a Generic XXXXX (XXXXX Labs Inc) to XXXXX (XXXXX lotion) Topical lotion XX% (XXXXX Labs Inc.) in the Treatment of Inflammatory Papules and Pustules of Rosacea Principal Investigator: An Open-Label, Long-term Extension Study to Assess the Safety of XXXXX in the Treatment of Psoriasis in Adult Subjects Principal Investigator: A Randomized, Double-Blind, Parallel-Group, Multicenter, Vehicle-Controlled Study of XXXXX 0.1% Cream Once Daily (qd) and Twice Daily (bid) in the Treatment of Plaque-Type Psoriasis Principal Investigator: A Randomized, Double-Blind, Parallel Group, Multicenter, Vehicle-Controlled Study of XXXXX 0.l% Cream Once Daily (qd) and Twice Daily (bid) in the Treatment of Atopic Dermatitis Principal Investigator: A Multicenter, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study to Determine the Therapeutic Equivalence of Two XXXXX Lotion Formulations in Subjects with Rosacea Principal Investigator: A Phase II, Double Blind, Placebo Controlled Randomized Study of XXXXX Administered by 12 Weekly Intravenous Infusions Principal Investigator: A Randomized, Double-Blind, Double Dummy, Placebo-Controlled Study of the Safety and Efficacy of XXXXX versus XXXXX in the Treatment of Seborrheic Dermatitis Principal Investigator: A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of XXXXX in the Treatment of Mild to Moderate Plaque-type Psoriasis of Non-Scalp Regions Principal Investigator: A Randomized, Double-Blind,Vehicle-Controlled, Multicenter Trial to Assess The Safety and Efficacy of XXXXX in the Treatment of Psoriasis on the Face or Intertriginous (Inverse) Areas Principal Investigator: Phase IIIb, Open-Label Effectiveness and Safety Study of XXXXX Topical Cream in the Treatment of Actinic Keratoses Principal Investigator: An Open Labeled, Multicenter Efficacy and Tolerability Study of XXXXX and XXXXX; XXXXX and XXXXX; XXXXX and XXXXX; XXXXX and XXXXX in Patients with Acne Vulgaris Principal Investigator: An Open Long-term Extension Study to Assess the Safety of XXXXX in the Treatment of Psoriasis in Adult Subjects Principal Investigator: A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Subcutaneously Administered XXXXX in the Treatment and Re-Treatment of Subjects with Moderate to Severe Plaque Psoriasis Principal Investigator: A Multi-Center Study to Assess the Impact of Topical Corticosteroids on the Safety and Efficacy of XXXXX in the Short-Term Treatment of Atopic Dermatitis and to Assess XXXXX in the Long-Term Management of Atopic Dermatitis Principal Investigator: A Phase IV, Multicenter, Open-Label, Randomized Study of the Safety and Efficacy of Low-Dose XXXXX (XXXXX) for the Treatment of Moderate to Severe Plaque-Type Psoriasis
Prinicipal Investigator: A Randomized, Double-Blind, Parallel Group, Multicenter, Phase 3 Extension,
Efficacy and Safety Study of XXXXX or XXXXX Placebo Combined with Oral XXXXX in the Treatment
of Onychomycosis
Principal Investigator: An Open Label, Single Group, Multicenter, Phase 3 Extension Study to Assess the
Maintenance Use of XXXXX in the Treatment of Onychomychosis
Principal Investigator: A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety
and Efficacy of XXXXX, XXXXX, in the Treatment of Mild to Severe Atopical Dermatitis
Principal Investigator: An Open-Label, Multicenter, Observational Phase IV Trial of XXXXX by
Community-based Dermatologists to Assess Effectiveness, Tolerability, and Subject Satisfaction, When
Used Once Daily for 12 Weeks as Add-on Therapy or Combination Therapy in Currently Untreated
Subjects, with Moderate to Moderately Severe Facial Acne Vulgaris
Principal Investigator: A Phase I, Double-Blind, Randomized, Placebo-Controlled,Multicenter Study
Evaluating the Safety and Tolerability of a Multidose Regimen of XXXXX Topically Applied to
Superficial or Nodular Basal Cell Carcinoma
Principal Investigator: XXXXX Epidemiologic Study of Psoriasis Outcomes and Safety Events in Patients
with Chronic Moderate to Severe Plaque Psoriasis
Principal Investigator: A Prospective Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of
XXXXX for the Treatment of Atopic Dermatitis

Community Service:
Multiple Skin Cancer Screenings – American Academy of Dermatology/Lankenau Hospital
Lankenau Independent Clinic Volunteer Services
Oil of Olay Skin cancer Awareness Training/Screening Program

Source: http://farberdermatology.com/wordpress/wp-content/uploads/2011/01/dr-farber-credentials-resume.pdf

Jpcooke_resume_srprojectmanager

J. Patrick Cooke // Sr. Project Manager Professional Experience May 2013 – September 2013 // Blast Radius / Wunderman World Health, New York, NY As a Sr. PM at Blast Radius I was responsible for the day-to-day management activities on the entire Novartis Gas-X account, as well as portions of the Novartis Prevacid account. Including but not limited to financial forecasting and budgeting

Gmail - update - monster manual v, shadowdale, magic 10th edi.

Gmail - Update - Monster Manual V, Shadowdale, Magic 10th Editio. http://mail.google.com/mail/?ik=fcb735a570&view=pt&th=113c217e. Niels Risgaard Hansen <niels.risgaard.hansen@gmail.com> Update - Monster Manual V, Shadowdale, Magic 10th Edition, Winds of Plunder, Star Fleet Battles 1 meddelelse Noble Knight Games <nobleknight@nobleknight.com> 14. ju

Copyright © 2010-2014 Pharmacy Drugs Pdf